Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen

doi:10.1016/S0140-6736(14)60525-0

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Fritz H Schröder, Jonas Hugosson, Monique J Roobol, Teuvo L J Tammela, Marco Zappa, Vera Nelen, Maciej Kwiatkowski, Marcos Lujan, Liisa Määttänen, Hans Lilja, Louis J Denis, Franz Recker, Alvaro Paez, Chris H Bangma, Sigrid Carlsson, Donella Puliti, Arnauld Villers, Xavier Rebillard, Matti Hakama, Ulf-Hakan StenmanPaula Kujala, Kimmo Taari, Gunnar Aus, Andreas Huber, Theo H van der Kwast, Ron H N van Schaik, Harry J de Koning, Sue M Moss, Anssi Auvinen

Research output: Contribution to journal › Article › peer-review

Abstract

The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis. We provide updated results of mortality from prostate cancer with follow-up to 2010, with analyses truncated at 9, 11, and 13 years.

Original language	English
Pages (from-to)	2027-2035
Journal	The Lancet
Volume	384
Issue number	9959
DOIs	https://doi.org/10.1016/S0140-6736(14)60525-0
Publication status	Published - 2014

Subject classification (UKÄ)

Medicinal Chemistry

Access to Document

10.1016/S0140-6736(14)60525-0

http://www.ncbi.nlm.nih.gov/pubmed/25108889?dopt=Abstract

Cite this

Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., Denis, L. J., Recker, F., Paez, A., Bangma, C. H., Carlsson, S., Puliti, D., Villers, A., Rebillard, X., Hakama, M., ... Auvinen, A. (2014). Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. The Lancet, 384(9959), 2027-2035. https://doi.org/10.1016/S0140-6736(14)60525-0

@article{08f826e47e0e489a869a7387e4206df7,

title = "Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.",

abstract = "The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis. We provide updated results of mortality from prostate cancer with follow-up to 2010, with analyses truncated at 9, 11, and 13 years.",

author = "Schr{\"o}der, {Fritz H} and Jonas Hugosson and Roobol, {Monique J} and Tammela, {Teuvo L J} and Marco Zappa and Vera Nelen and Maciej Kwiatkowski and Marcos Lujan and Liisa M{\"a}{\"a}tt{\"a}nen and Hans Lilja and Denis, {Louis J} and Franz Recker and Alvaro Paez and Bangma, {Chris H} and Sigrid Carlsson and Donella Puliti and Arnauld Villers and Xavier Rebillard and Matti Hakama and Ulf-Hakan Stenman and Paula Kujala and Kimmo Taari and Gunnar Aus and Andreas Huber and {van der Kwast}, {Theo H} and {van Schaik}, {Ron H N} and {de Koning}, {Harry J} and Moss, {Sue M} and Anssi Auvinen",

year = "2014",

doi = "10.1016/S0140-6736(14)60525-0",

language = "English",

volume = "384",

pages = "2027--2035",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9959",

}

Schröder, FH, Hugosson, J, Roobol, MJ, Tammela, TLJ, Zappa, M, Nelen, V, Kwiatkowski, M, Lujan, M, Määttänen, L, Lilja, H, Denis, LJ, Recker, F, Paez, A, Bangma, CH, Carlsson, S, Puliti, D, Villers, A, Rebillard, X, Hakama, M, Stenman, U-H, Kujala, P, Taari, K, Aus, G, Huber, A, van der Kwast, TH, van Schaik, RHN, de Koning, HJ, Moss, SM & Auvinen, A 2014, 'Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.', The Lancet, vol. 384, no. 9959, pp. 2027-2035. https://doi.org/10.1016/S0140-6736(14)60525-0

TY - JOUR

T1 - Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

AU - Schröder, Fritz H

AU - Hugosson, Jonas

AU - Roobol, Monique J

AU - Tammela, Teuvo L J

AU - Zappa, Marco

AU - Nelen, Vera

AU - Kwiatkowski, Maciej

AU - Lujan, Marcos

AU - Määttänen, Liisa

AU - Lilja, Hans

AU - Denis, Louis J

AU - Recker, Franz

AU - Paez, Alvaro

AU - Bangma, Chris H

AU - Carlsson, Sigrid

AU - Puliti, Donella

AU - Villers, Arnauld

AU - Rebillard, Xavier

AU - Hakama, Matti

AU - Stenman, Ulf-Hakan

AU - Kujala, Paula

AU - Taari, Kimmo

AU - Aus, Gunnar

AU - Huber, Andreas

AU - van der Kwast, Theo H

AU - van Schaik, Ron H N

AU - de Koning, Harry J

AU - Moss, Sue M

AU - Auvinen, Anssi

PY - 2014

Y1 - 2014

N2 - The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis. We provide updated results of mortality from prostate cancer with follow-up to 2010, with analyses truncated at 9, 11, and 13 years.

AB - The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis. We provide updated results of mortality from prostate cancer with follow-up to 2010, with analyses truncated at 9, 11, and 13 years.

U2 - 10.1016/S0140-6736(14)60525-0

DO - 10.1016/S0140-6736(14)60525-0

M3 - Article

VL - 384

SP - 2027

EP - 2035

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9959

ER -

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this